DOJ Sues NYP for Sherman Act Antitrust Violations
The DOJ and U.S. Attorney's Office for the Southern District of New York filed a civil antitrust lawsuit against New York-Presbyterian Hospital (NYP), alleging Section 1 Sherman Act violations through anti-competitive contract provisions with commercial payors. The government seeks injunctive relief and a declaratory judgment that NYP's contract restrictions violate antitrust law.
Healthcare Digital Accessibility Standards Under Section 504
HHS Office for Civil Rights issued a final rule updating Section 504 regulations, establishing WCAG 2.1 Levels A and AA as the technical standard for digital accessibility. Recipients of HHS federal financial assistance—including hospitals, physician practices, health plans, and medical schools—must ensure websites and mobile apps comply. Organizations with 15+ employees have until May 11, 2026; those with fewer than 15 employees until May 10, 2027.
DOJ v. NewYork-Presbyterian - Hospital Antitrust Contract Restrictions
The DOJ Antitrust Division filed a civil lawsuit against NewYork-Presbyterian (NYP) in the US District Court for the Southern District of New York, alleging violations of Section 1 of the Sherman Act. The complaint alleges NYP's contracts with commercial payors contain 'all-or-nothing' and most favored nation provisions that prevent development of budget-conscious health plans. This marks the second DOJ antitrust action against hospital system contracting practices in 2026, following a similar suit against OhioHealth.
OIG approves ASC estate planning transfers with safeguards
HHS-OIG issued Advisory Opinion AO-26-04 on March 4, 2026, providing a favorable opinion on proposed estate planning transfers of ownership in a Medicare-certified ASC. The opinion addresses transfers from a sole-physician owner to his spouse, surgeon children, and eventual estate beneficiaries. OIG determined the arrangement would not impose sanctions under the Anti-Kickback Statute when safeguards including independent third-party fair market value appraisals and physician non-referral certifications are in place.
Pharma Data Privacy and Cybersecurity under the Trump Administration
HHS has proposed significant updates to the HIPAA Security Rule that would represent one of the most consequential federal healthcare cybersecurity updates in years. The proposed changes would require comprehensive technology asset inventories, network maps, detailed risk analyses, stronger encryption, multifactor authentication, periodic vulnerability scanning, annual penetration testing, and formal disaster-recovery capabilities. Pharmaceutical companies operating adjacent to HIPAA-regulated workflows face new compliance obligations even when not directly covered entities.
Trump Administration Impact on Pharmaceutical Industry - State AG Oversight, Data Privacy, and Pricing
Foley & Lardner LLP published an analysis of the Trump administration's impact on the pharmaceutical industry after one year in office. The analysis identifies three primary regulatory pressure areas: increased State Attorney General enforcement as federal agency staffing declines, heightened data privacy concerns, and pharmaceutical pricing pressures. The firm announces an ongoing blog series to track developments in corporate, regulatory, and intellectual property law affecting life sciences companies.
Oral Cancer Awareness and Early Detection Guidance
The Alabama Department of Public Health issued an informational notice for Oral Cancer Awareness Month (April 2026) highlighting that 72% of oral cancers are HPV-caused. The notice provides statistics showing approximately 53,260 expected diagnoses nationally in 2026, and Alabama-specific data including 7,886 total diagnoses between 2014-2023. The notice emphasizes early detection through routine dental exams and promotes HPV vaccination for ages 9-45.
CMS Hemp-Derived Products Beneficiary Engagement Incentive
CMS announced a new Substance Access Beneficiary Engagement Incentive (BEI) allowing participating Accountable Care Organizations in the ACO REACH and Enhancing Oncology Models to offer eligible hemp-derived products valued at up to $500 per year per beneficiary. Five ACOs have submitted implementation plans for CMS review, with approved participants able to begin offering the incentive starting April 1, 2026.
Abilify Mycite Trademark Renewal - Digital Medicine Sensor System
USPTO renewed Trademark Registration TM99309131 for ABILIFY MYCITE, covering pharmaceutical preparations with electronic ingestion tracking chips, downloadable mobile applications for patient data collection, and body-attached sensor patches for monitoring vital signs. The trademark covers Class 10 medical devices and Class 5 pharmaceuticals for digital medicine systems.
NOVOBURN Trademark Application - Medical Devices Class 10
The USPTO received a trademark application (TM99340004) for 'NOVOBURN' in International Class 10 covering medical devices including surgical tissue reconstruction grafts, bioresorbable polymer scaffolds for burn and wound care, artificial skin for medical purposes, and biodegradable prosthetic tissues. The application is filed on an Intent-to-Use basis with a deadline of March 31, 2026 for statement of use.
INNOTOT Intent to Use Trademark Application - Medical Devices Class 10
USPTO published an Intent to Use trademark application for INNOTOT (TM99336872) covering goods in Class 10 including feeding bottles, breast pumps, feeding bottle valves, sex toys, love dolls, and orthopaedic belts. The application was filed on August 14, 2025, with a declaration of use deadline of March 31, 2026. This is an informational notice with no new obligations for third parties.
NANOACTIV Medical Instruments Trademark Application
USPTO published trademark application TM99335625 for NANOACTIV covering medical instruments including spinal implants and orthopedic surgical apparatus in International Class 10. The application was filed August 13, 2025, under Intent-to-Use basis with a Statement of Use extension deadline of March 31, 2026.
IQUITY medical instruments, ophthalmic apparatus trademark application
IQUITY medical instruments, ophthalmic apparatus trademark application
THE ATAXI Medical Walker Trademark Application
The USPTO received trademark application TM99344829 for THE ATAXI covering medical walkers, rollators, and adjustable sit-to-stand assistive devices for mobility-impaired individuals. The application was filed on August 19, 2025, under Class 10 (Medical Devices) with a Statement of Use deadline of March 31, 2026. Medical device manufacturers and trademark applicants should review the applied-for mark for potential conflicts.
SOMZOKY Trademark Application for Medical Instruments and Devices
USPTO received trademark application TM99342577 for SOMZOKY covering medical instruments and devices including ear plugs, nasal irrigation vessels, breast pumps, blood glucose meters, and blood pressure monitors. The application filed August 18, 2025, is based on Intent to Use with a proposed use date of March 31, 2026.
Bradford Vagus Connection Trademark Application for Medical Electrodes
USPTO received trademark application TM99340210 for 'Bradford Vagus Connection' filed by Bradford, covering electrodes for medical use. The application is based on Intent-to-Use, with the goods described as electrodes for medical purposes in Class 10. No compliance deadlines or regulatory requirements are imposed on third parties by this filing.
MIRUSMED trademark for medical instruments
The USPTO received trademark application TM99349152 for 'MIRUSMED' covering medical instruments including orthopedic fixation devices, medical implants, vascular implants, bone screws, stents, artificial heart/cardiac valves, spinal implants, cervical plates, and related surgical devices and monitoring equipment. The application was filed on 2025-08-21 under Intent-to-Use basis with an extension deadline of March 31, 2026. This is an informational trademark filing notice and creates no compliance obligations for competitors.
Nanoguard Trademark Application for Medical Bandages
The USPTO received Intent-to-Use trademark application TM99348554 for 'NANOGUARD' covering Class 10 medical device products including elastic compression bandages, orthopedic support bandages, and hernia bandages for surgical and medical purposes. The applicant has until March 31, 2026 to file a Statement of Use demonstrating commercial use of the mark.
Amhavor Trademark Application - Medical Devices and Cosmetic Apparatus
The USPTO received trademark application TM99346186 for AMHAVOR filed on August 19, 2025. The application covers medical devices and cosmetic apparatus including hearing aids, laser treatment devices, light therapy equipment, and skin care analyzers under International Class 10. The applicant has declared Intent to Use, with a deadline of March 31, 2026 to demonstrate commercial use.
WEGO SUTURES Trademark - Medical Suture Devices
The USPTO renewed Trademark Registration TM99349357 for WEGO SUTURES. The registration covers Class 10 medical device goods including vascular hemostasis devices, surgical needles, suture materials, and related medical instruments. No substantive changes to the scope of protection were made.
Novurial Intent-to-Use Trademark - Medical Devices
USPTO received Intent-to-Use trademark application TM99351314 for NOVURIAL covering Class 10 medical device goods including LED light therapy apparatus, nebulizers, oxygen concentrators, and phototherapeutic devices. The application was filed on August 22, 2025 with a stated intent to use the mark in commerce.
MIRUS intent to use trademark for medical devices
MIRUS intent to use trademark for medical devices
Adaptadrip Medical Infusion Device Trademark Application
USPTO received an Intent to Use trademark application for ADAPTADRIP covering portable medical accessories for suspending fluids and medical infusion devices for administering drugs. Application TM99350875 was filed on August 21, 2025, with a declared intent to use date of March 31, 2026.
EU Pharma Package - Stricter Environmental Risk Assessment Rules for Pharma
The EU Council and Parliament have finalized the Pharma Package, introducing stricter Environmental Risk Assessment (ERA) requirements for pharmaceutical companies. The new rules extend ERA obligations to manufacturing and antimicrobial resistance, add ongoing monitoring requirements beyond initial MA application snapshots, and introduce real consequences for non-compliance including potential MA suspension or revocation.
CMS extends 36-month rule to DMEPOS suppliers
CMS extends 36-month rule to DMEPOS suppliers
Johnson v. Amazon.com Services - Wage Compensation for Pre-Shift Activities
The Illinois Supreme Court in Lisa Johnson v. Amazon.com Services, LLC ruled that under the Illinois Minimum Wage Law (IMWL), employers must compensate nonexempt employees for preliminary and postliminary activities such as pre-shift COVID-19 screenings. This decision diverges from federal law under the Portal-to-Portal Act (PPA), which excludes such activities from compensable time. The ruling applies to all employers with nonexempt employees in Illinois and may expose them to class action liability for unpaid screening time.
Digital Accessibility Requirements for Healthcare Websites, Apps, and Kiosks
HHS finalized a rule requiring recipients of federal financial assistance to make their websites, mobile applications, and kiosks accessible to individuals with disabilities per WCAG 2.1 Level AA standards. Large recipients with 15 or more employees must comply by May 11, 2026; small recipients with fewer than 15 employees have until May 10, 2027. Covered entities include healthcare providers accepting Medicare or Medicaid, health plans, and social services.
Healthcare Private Equity Outlook Conference Takeaways
McDermott Will & Schulte published conference takeaways from HPE Miami 2026, a healthcare private equity summit attended by over 2,000 industry leaders. The report identifies operational execution, compliance and quality management, and talent leadership as key determinants of near-term PE performance. Deal momentum is driven by health IT and AI-enabled services according to 47% of poll respondents.
REFORM MD trademark application for medspa services
USPTO received trademark application TM99334368 for 'REFORM MD' covering medspa services for health and beauty of the body and spirit. The application was filed August 13, 2025, under Intent to Use basis with a Statement of Use deadline of March 31, 2026.
Unique Behavior Supports trademark for autism services
USPTO received trademark application TM99325262 for 'UNIQUE BEHAVIOR SUPPORTS & SERVICES' covering educational and behavioral health services for individuals with autism and developmental disorders. The application, filed August 7, 2025, is an Intent-to-Use filing with a March 31, 2026 deadline to demonstrate commercial use. This is a routine trademark filing that does not impose obligations on third parties.
Phenytoin Sodium Capsules and Chewable Tablets Shortage Notice
Health Canada issued a notice advising that phenytoin sodium capsules and chewable tablets are in short supply until early May 2026. BGP Pharma's Dilantin products and AA Pharma's capsules are constrained, with Taro's oral suspension unable to compensate. Health Canada is coordinating with provincial and territorial governments and stakeholders to manage the shortage.
Nelkarmi Pharmaceutical Trademark - Oncology
USPTO received trademark application TM99192492 for 'NELKARMI' covering pharmaceutical preparations for oncology diseases and disorders on May 19, 2025. The application was filed under Intent-to-Use provisions with a deadline of March 31, 2026 for the Statement of Use.
DERMOLECULE intent-to-use trademark filed for skincare
DERMOLECULE intent-to-use trademark filed for skincare
Aloe Jack Trademark Application - Class 005
The USPTO received a new Intent-to-Use trademark application (TM99226264) for 'ALOE JACK' in Class 005 covering personal lubricants and medicated body care preparations containing aloe as an active ingredient. The application was filed on June 10, 2025. This filing does not create any compliance obligations for third parties.
Bioharmony trademark renewal Class 005 nutritional supplements
The USPTO renewed trademark registration TM99281541 for BIOHARMONY covering dietary supplements, mineral food supplements, and nutritional supplements. The renewal was processed on March 31, 2026. This is a routine trademark maintenance action with no new obligations for the trademark holder.
TORESSENCE Trademark Application - Intent to Use
The USPTO has published Intent to Use trademark application TM99241954 for TORESSENCE, filed on June 18, 2025. The application covers dietary and nutritional supplements, non-medicated anti-aging serum, cosmetics, and hair care preparations in Class 005. This publication initiates the opposition period during which third parties may challenge the mark.
RETORQ1 Intent to Use Trademark for Supplements and Cosmetics
USPTO received an Intent to Use trademark application for RETORQ1 (TM99242010) filed June 19, 2025. The application covers dietary supplements, nutritional supplements for menopause, non-medicated anti-aging serum, cosmetics, and hair care preparations.
Dr. Mariem Health and Wellness Trademark Application
The USPTO received Trademark Application TM99243544 from Dr. Mariem Health and Wellness on June 19, 2025, filed under Intent-to-Use basis. The application covers medicated cosmetics, vitamin supplements, calcium supplements, dietary supplements, and nutritional supplements under Class 005. No compliance obligations are imposed on third parties.
AVEENO Clear + Soothe Trademark Application
The USPTO received an intent-to-use trademark application (TM99254469) for AVEENO CLEAR + SOOTHE filed by Johnson & Johnson Consumer Inc. on June 26, 2025. The application covers International Class 005 goods including acne treatment preparations, medicated acne cleansers, and non-medicated skin care preparations. This is a standard trademark filing with no immediate regulatory implications for other parties.
Bryndall Trademark Renewal - Nutritional Supplements
USPTO renewed Bryndall trademark registration TM99255655 covering nutritional supplements. The registration covers probiotic compositions, herbal supplements, vitamin and mineral supplements, dietary supplements, and related products for humans and animals. Trademark protection extended through this renewal.
Sage One Trademark Renewal - Beverages and Dietary Supplements
The USPTO renewed trademark registration TM99257949 for SAGE ONE, extending registration protection through March 31, 2026. The mark covers non-alcoholic beverages including energy drinks, flavored waters, and iced tea, as well as dietary supplements, nutritional supplements, and related products.
VIMALKA Trademark - Pharmaceutical Oncology Preparations
USPTO filed trademark application TM99192483 for VIMALKA on May 19, 2025, covering pharmaceutical preparations and products for oncology diseases and disorders under Nice Class 005. The application is classified as Intent-to-Use, indicating the applicant plans to use the mark in commerce.
DELKARMI Trademark Application - Oncology Pharmaceuticals
USPTO received trademark application TM99192498 for DELKARMI, filed May 19, 2025, for pharmaceutical preparations for use in oncology diseases and disorders under Class 005. The application is filed under Intent-to-Use provisions with a stated deadline of March 31, 2026.
JUSTCENTER FOR REPRODUCTIVE HEALTH Trademark Application
USPTO received trademark application TM99331828 for 'JUSTCENTER FOR REPRODUCTIVE HEALTH' filed August 11, 2025. The application covers medical clinic services, telemedicine, and health information in reproductive and sexual health. This is an Intent-to-Use application with standard 8-month processing period.
Kopp Foundation for Diabetes Trademark Application
The USPTO received Trademark Application TM99320945 from Kopp Foundation for Diabetes, filed August 5, 2025, seeking registration for services related to providing information in the field of diabetes. The application is filed on an Intent-to-Use basis under Class 044 (Medical Services).
PRESERVATION AUGMENTATION Trademark - Medical Services (Class 044)
USPTO received trademark application TM99313706 for "PRESERVATION AUGMENTATION" in Class 044 (Medical Services) for breast augmentation procedures. The application was filed on July 31, 2025, under an Intent-to-Use basis with a deadline of March 31, 2026, to demonstrate actual use in commerce.
Trademark Application for Comprehensive Spinal Restoration Treatment
USPTO received trademark application TM99329685 for "COMPREHENSIVE SPINAL RESTORATION TREATMENT (CSRT)" covering chiropractic services, filed August 10, 2025. The application is filed on an intent-to-use basis with an extension period through March 31, 2026. This is a routine trademark filing establishing priority rights for the specified medical service mark.
Measles case reported in Ransom County, North Dakota
North Dakota Health and Human Services reported one confirmed measles case in Ransom County, the first case in that county. The individual likely acquired the infection within the state and has no linked travel history. North Dakota has 27 total confirmed measles cases in 2026 with five hospitalizations. The case is not linked to the existing Pembina County outbreak.
IV Vibes mobile hydration trademark application
USPTO received trademark application TM99319324 for 'IV VIBES' covering mobile healthcare services under Class 44 (Medical Services), filed August 4, 2025. The applicant has declared intent to use the mark, with a use-in-commerce deadline of March 31, 2026. This is an informational notice of a trademark filing with no new compliance obligations.
Gun Safety Awareness Campaign Launched
New Mexico Department of Health launched a statewide multi-media awareness campaign on free gun locks and the Extreme Risk Firearm Protection Order law. Since September 2023, NMDOH has distributed over 88,746 free gun locks. The campaign was developed in partnership with the New Mexico Department of Public Safety.
Longtab Quantum Medicine Trademark Application for Medical Services
The USPTO published a trademark application (TM99264647) for LONGTAB QUANTUM MEDICINE, PLLC covering medical services in Class 044. The application, filed July 2, 2025, covers alternative medicine, detoxification, regenerative medicine, mental health counseling, wellness programs, and managed healthcare services. This is an Intent-to-Use application with a deadline of March 31, 2026.
Ortho Vision Max Immuno-Hematology Device Safety Alert
ANSM issued a safety information notice (Ref. R2608831) regarding a safety action by QuidelOrtho for Ortho Vision Max and Ortho Vision automated immuno-hematology analyzers. Medical analysis laboratories using these devices have received direct correspondence from the manufacturer about the safety measure. Users with questions should contact QuidelOrtho directly.
Recall of Milestone Vacuum Bags - Burn Hazard
ANSM registered recall action R2607842 for Milestone vacuum bags manufactured by Microm Microtech. The recall was initiated due to burn hazard identified in affected products distributed to medical biology laboratories. Users have received notification letters with instructions for returning the recalled items.
Mitomycine Substipharm 20 mg Filter Update for Injection Administration
ANSM issued an updated safety notice for Mitomycine Substipharm 20 mg, permanently including a Millex HV filter (0.45 μm / PVDF) with reconstitution vials. The agency clarified that filtration remains mandatory for intravenous, intra-arterial, and intra-serous administration but is no longer required for intravesical administration. Healthcare professionals in urology, oncology, and related specialties should update their administration protocols accordingly.
Total Knee Replacement Tibial Insert Recall - Exatech Optetrak Logic
ANSM issued a safety alert (R2608390) regarding a lot recall for tibial inserts used in the Optetrak Logic total knee replacement system, manufactured by Exatech Inc. The recall affects hospital pharmacies and surgical centers using these devices. Healthcare facilities must identify and remove the affected lot from inventory.
VANTECH DENTAL PARTNERS trademark application for dental care services
USPTO received trademark application TM99293398 for VANTECH DENTAL PARTNERS covering dental care services. The application is filed under Intent-to-Use basis with a deadline of March 31, 2026 to demonstrate actual use in commerce.
ACTIVATOR LONGEVITY CENTER Trademark - Medical Services Class 044
USPTO received trademark application TM99275393 for 'ACTIVATOR LONGEVITY CENTER' filed 2025-07-09 under Intent to Use for health and wellness center services, geriatric health care management, and related healthcare services in Class 044. Application is currently pending.
PETMEDS Intent-to-Use Trademark Application
PetMed Express filed an intent-to-use trademark application (TM99007390) with USPTO covering online and retail store services for pet supplies, veterinary pharmacy services, pet medications, and nutritional products. The application also covers non-medicated pet care products including shampoos, ear cleaners, grooming preparations, and pet food/treats.
Oncopure trademark, custom biological products, oncology applications
USPTO received trademark application TM99112549 from Oncopure for the ONCOPURE mark in International Class 5 (pharmaceuticals/biologics). The application covers custom biological products for oncology applications including reference standards, nucleic acids, and FFPE samples for research and clinical testing purposes. Filing date is March 31, 2025, with intent-to-use basis and a published abstract date of March 31, 2026.
ONCOSPAN Trademark Application for Oncology Research Products
USPTO received trademark application TM99112500 for 'ONCOSPAN' filed March 31, 2025, by a single applicant seeking protection for biological preparations, cell line-derived reference standards, and custom manufacturing services for oncology research products. The application covers goods in International Class 5 including nucleic acid reference standards, FFPE samples, and custom manufactured biological products for clinical diagnostics.
Kobuk Therapeutics trademark application for pharmaceutical preparations
The USPTO received trademark application TM99107436 for 'KOBUK THERAPEUTICS' filed by Kobuk Therapeutics on March 27, 2025. The application covers pharmaceutical preparations and medicines in Nice Class 5 for the treatment of viral, metabolic, cardiovascular, oncological, neurological, and other disease categories. This is an Intent-to-Use application, indicating the applicant plans to use the mark in commerce.
MEDTIDE Trademark Application
USPTO received an Intent to Use trademark application (TM99057317) for MEDTIDE filed by an unidentified applicant on March 31, 2026. The application covers International Class 005, encompassing pharmaceutical preparations, biopharmaceuticals, diagnostic preparations, chemical compounds for pharmaceutical manufacturing, and medical/therapeutic treatments. No compliance obligations arise from this filing; it represents a standard trademark registration record.
PCOE Trademark Application - Home Health Care Services
The USPTO received a trademark application (TM99208673) for the word mark PCOE in connection with home health care services for medically complex pediatrics. The application was filed on May 29, 2025, under an Intent-to-Use basis with an extension deadline of March 31, 2026. This filing does not establish new regulatory obligations but provides notice of the mark for public review.
New Jersey APNs gain independent practice, prescriptive authority
New Jersey Governor signed legislation on March 30, 2026, permitting qualified Advanced Practice Nurses (APNs) to practice and prescribe independently without joint protocols with physicians. Qualifying APNs must have over 5,000 hours of clinical experience in primary care (family/individual across lifespan), women's health, or behavioral health settings. The law establishes new continuing education, malpractice coverage, notice, and disclosure requirements.
Informal HIPAA Q&A Guidance on Patient Communications
HHS published informal Q&A guidance clarifying HIPAA Privacy Rule requirements for patient communications. The guidance addresses when covered entities may leave appointment or prescription reminders via voicemail, mail, or with family members, and when they must accommodate requests for confidential communications. Healthcare professionals should note this guidance is informal and may be updated.
Healthcare Deal Decks Risk Referral Law Violations
JD Supra published an analysis on April 1, 2026 warning healthcare organizations that deal materials (investor decks, board presentations, data room documents) can inadvertently create referral law compliance risks. The article identifies specific phrases and presentation formats that diligence teams may interpret as referral steering plans, including language around internal pipelines, capturing ancillaries, and driving cases to ASCs. Compliance officers and deal teams are advised to review materials for problematic language before transactions.
DERMA-CLEAR trademark for medical micro-extraction instruments
USPTO received trademark application TM99295614 for 'DERMA-CLEAR' covering medical instruments for micro-extraction of cellular tissue and surgical instruments for micro-extraction of cellular tissue. The application was filed on July 22, 2025 under an Intent-to-Use basis. This is a routine trademark filing that does not impose new regulatory obligations on the medical device industry.
SpaceOAR Flex Medical Hydrogel Trademark Application
The USPTO received a trademark application (TM99295958) for SPACEOAR FLEX, filed on July 22, 2025. The application covers pharmaceutical preparations in the nature of implantable synthetic hydrogel for medical and surgical purposes treating prostate cancer, as well as a medical device consisting of pre-polymerized hydrogel for related procedures. The application is filed under Intent to Use with an extension deadline of March 31, 2026.
Lighteum Medical Trademark - Medical Device Components
USPTO published a trademark application for Lighteum Medical covering metal substrates for medical device manufacture, medical device components (electrodes, radiopaque markers, medical wires, catheter parts), and custom manufacturing services. The application (TM99286673) was filed July 16, 2025, under Intent-to-Use with a use-in-commerce deadline of March 31, 2026.
PULMOVISTA Trademark Application for Pulmonary Monitoring Devices
USPTO filed trademark application TM99263947 for PULMOVISTA covering pulmonary monitoring devices, electrical impedance tomographs, and patient monitors for use with anesthesia machines and respirators. The application is categorized as Intent-to-Use with a stated due date of March 31, 2026.
Edition Plastic Surgery Trademark Application
USPTO received an Intent-to-Use trademark application for 'Edition Plastic Surgery' (Serial No. TM99189635) on May 16, 2025. The application covers medical services including plastic surgery, cosmetic skin care, and surgical body shaping services. The application is currently in draft/pending status with an amendment deadline of March 31, 2026.
LONGTAB QUANTUM MEDICINE Trademark Application - Class 044
USPTO published a trademark application for "LONGTAB QUANTUM MEDICINE" (Serial No. TM99249874) covering medical services in Class 044 including alternative medicine, emergency clinics, sports and regenerative medicine, mental health counseling, wellness programs, and managed healthcare. The application was filed June 24, 2025 under Intent to Use provisions with an extension deadline of March 31, 2026. Third parties have until that date to file opposition if they believe the mark could cause confusion with existing marks.
NCHS Research Data Center Forms
CDC's National Center for Health Statistics (NCHS) Research Data Center issued a notice regarding required forms for data access requests. The notice establishes a compliance deadline of June 1 for form submissions. This routine administrative update affects researchers and institutions seeking to access NCHS restricted-use data files through the Research Data Center.
Spongetrac surgical sponge monitor trademark application
The USPTO received trademark application TM99278631 for "SPONGETRAC" filed by an undisclosed applicant on July 11, 2025. The mark covers an electronic surgical sponge monitor system and disposable container for medical waste used in operating rooms. This is an Intent-to-Use application with no current use in commerce.
Lyme Disease Treatment Centers of America Trademark Application - Intent to Use
USPTO received an Intent to Use trademark application (TM99200378) for 'LYME DISEASE TREATMENT CENTERS OF AMERICA' covering medical services including Lyme disease treatment, treatment protocol design, and medical analysis services. The application was filed on May 23, 2025, with a stated intent to use date of March 31, 2026. This is an informational filing announcing a trademark registration proceeding rather than an enforcement action or regulatory requirement.
New outcomes-driven certifications in perinatal and cardiac care
The Joint Commission announced two new voluntary outcomes-driven certifications for hospitals in perinatal care and cardiac surgeries/procedures. The certifications shift from process-based compliance to measuring actual clinical outcomes, using data from established clinical registries including STS and ACC. Healthcare organizations seeking recognition for quality performance can apply for these new certifications.
Ultraview SL Command Module Cardiac Output Defect Recall
Health Canada issued a Type II recall for Spacelabs Healthcare's Ultraview SL™ Command Module (model 91496) after production testing discovered the cardiac output function was intermittently yielding bad or irregular curves. Healthcare providers using this multiparameter module should contact the manufacturer for lot information and assess any affected devices in their facilities.
Evoflex Spinal Implant Trademark Application
The USPTO received trademark application TM99207282 for 'EVOFLEX' covering medical devices, specifically spinal implants composed of artificial materials for surgical implantation. The application is filed under intent-to-use basis, indicating the applicant plans to use the mark in commerce but has not yet done so. The goods explicitly exclude wearable or externally applied medical devices.
NURVA Trademark - Medical Pain Relief Patches Class 10
USPTO published trademark application TM99172970 for NURVA covering medical devices in Class 10, specifically pain relief patches featuring nanotechnology for filtering pain signals. The application was filed on May 7, 2025, under an Intent-to-Use basis with a deadline of March 31, 2026, to demonstrate commercial use.
NOVOPREP Surgical Grafts and Implants Trademark
Novoprep filed a USPTO trademark application (TM99061096) for 'NOVOPREP' covering Class 10 medical device goods including surgical grafts, implants, artificial skin, scaffolds, and wound care materials. The application was filed on February 28, 2025, with an intent-to-use basis dated March 31, 2026.
Neuroaeye Medical Device Trademark Application
The USPTO received trademark application TM99007296 for 'NEUROAEYE' covering medical apparatus including diagnostic tools for visual field loss, treatment devices for visual field rehabilitation, and tools for detecting and rehabilitating visual midline shift and postural alignment. The application, filed January 17, 2025, is an Intent-to-Use application with a deadline to use the mark in commerce by March 31, 2026.
Antares More trademark for medical implant devices
The USPTO published a trademark application for ANTARES MORE (Serial No. TM99071631) covering Class 10 medical implant devices including vertebral implants, spinal implants, fixation implants, and orthopedic joint implants. The application was filed on March 6, 2025, under an Intent to Use basis with a priority date of March 31, 2026. This is a routine trademark filing that establishes priority rights for the applicant in connection with medical device branding.
Clear Airways First Medical Device Trademark
USPTO received trademark application TM99114918 for "CLEAR AIRWAYS FIRST" filed by an unnamed applicant on April 1, 2025. The application covers medical devices including airway clearance systems comprising air pulsing units connected to garments, as well as related health clinic support services. The application declares Intent to Use with a priority deadline of March 31, 2026.
Mirus Antares Trademark - Medical Implant Devices
USPTO received a trademark application from Mirus for 'MIRUS ANTARES' covering surgical and medical implant devices composed of artificial materials including vertebral implants, spinal implants, fixation implants, orthopedic joint implants, and surgical bone plates. The application (TM99071647) was filed on March 6, 2025, under Intent-to-Use provisions.
Psychiatry Connection trademark application for psychiatric mental health services
USPTO received trademark application TM99088438 for "PSYCHIATRY CONNECTION" filed on March 17, 2025. The application is an Intent-to-Use filing covering psychiatric mental health services. The application is currently pending examination.
Zilian Skin Trademark Application - Body Waxing Services
USPTO received trademark application TM99146727 for "ZILIAN SKIN" covering body waxing and cosmetic hair removal services in Class 044 (Medical Services, Beauty Services). The application was filed on April 21, 2025, under Intent-to-Use basis with a deadline of March 31, 2026 to demonstrate commercial use.
Mindfulness-Oriented Recovery Enhancement (MORE) app trademark
USPTO received Intent to Use trademark application TM99145919 for 'Mindfulness-Oriented Recovery Enhancement (MORE)' covering downloadable mobile software for reducing cravings, substance use, emotional distress, and pain, as well as related training and psychotherapy services. The applicant seeks to protect marks for healthcare provider training in mindfulness therapy, educational services in mind-body therapy and cognitive-behavioral skills, and telemedicine delivery of mental health services.
Vichy Integrative Health Trademark Application - Intent to Use
USPTO received trademark application TM99099736 from Vichy Integrative Health for 'Vichy Integrative Health Boosting Dermatology' filed March 24, 2025, based on intent-to-use. The application covers medical services, cosmetics, dietary supplements, and scientific research services across multiple International Classes.
VICHY Integrative Medical Health Trademark Application
USPTO received trademark application TM99096818 for 'VICHY INTEGRATIVE MEDICAL HEALTH' filed March 21, 2025. The application covers goods and services in Classes 3 and 44, including medical information services, cosmetics, chemical preparations, dietary supplements, and hair care preparations.
National Blood Collection and Utilization Survey Information Collection
The CDC published a Federal Register notice extending the public comment period for the proposed National Blood Collection and Utilization Survey (NBCUS). The survey is a biennial data collection effort designed to produce national and regional estimates of blood collections, utilization, and safety. Comments on the proposed information collection are due 30 days from the April 1, 2026 publication date.
ONC Health IT Organization and Authority Structure Updates
HHS published a Federal Register Notice on April 1, 2026, reorganizing ONC (Office of the National Coordinator for Health Information Technology) by reversing the management title of Assistant Secretary for Technology Policy and restoring ONC as a singularly titled office. The roles of the HHS Chief Technology Officer, Chief AI Officer, and Chief Data Officer will no longer be part of ONC, and the organizational structure is consolidated into three offices.
Acceptable Market Name Change for Certain Rockfish Species
The FDA issued a notice requesting data and information to support an evidence-based determination on potential updates to the acceptable market name for 18 Sebastes rockfish species. This consultation invites stakeholders to submit comments and supporting data on the proposed market name change by May 1, 2026.
Determination That INAPSINE Droperidol Injection Was Not Withdrawn From Sale for Safety
The FDA determined that INAPSINE (droperidol) injection, 2.5 mg/mL, was not withdrawn from sale for reasons of safety or effectiveness. This determination allows FDA to continue approving ANDAs (abbreviated new drug applications) that refer to this product, which is currently listed in the Orange Book's Discontinued Drug Product List. The drug was originally approved under NDA 016796 held by Akorn, Inc.
Priority Review Voucher Issuance for YUVIWEL Rare Pediatric Disease Product
The FDA announced the issuance of a priority review voucher to Ascendis Pharma Growth Disorders (A/S) for YUVIWEL (navepegritide), approved February 27, 2026. The drug is indicated to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses. This notice fulfills FDA's statutory requirement to publish awards of priority review vouchers under section 529 of the FD&C Act.
Petition to Remove Three Solvents from Color Additive Regulations
The FDA announced receipt of a color additive petition from the International Association of Color Manufacturers (IACM) requesting removal of three solvents from 21 CFR Part 73. The petition targets methylene chloride, trichloroethylene, and ethylene dichloride, citing permanent abandonment of these uses in color additive preparation. The FDA is seeking public comments through June 1, 2026.
HOWARU probiotic ingredient trademark application
The USPTO received a trademark application (TM98867137) from DuPont for the HOWARU probiotic ingredient mark under Intent-to-Use basis. The application covers goods including microbial cultures, dietetic foods for medical use, and infant formula. The deadline to demonstrate commercial use is March 31, 2026.
Vascudyne Trademark Application - Vascular Health Biotechnology
Vascudyne, a vascular health biotechnology company, filed Intent-to-Use trademark application TM98449022 with the USPTO on March 14, 2024. The application covers biotechnologically engineered tissue products including cells, tissue cell sheets, biological tissue grafts, and vascular grafts for medical purposes.
ADPTV Biosource Labs Trademark Application
USPTO received an Intent to Use trademark application TM98566010 from ADPTV Biosource Labs for dietary and nutritional supplements. The application was filed on May 23, 2024, with a stated intent to use date of March 31, 2026. This is a standard trademark registration proceeding in Class 005 covering pharmaceutical and dietary supplement products.
Medici Intent to Use Trademark - Cancer Treatments
The USPTO received a trademark application for "MEDICI" (Serial No. TM98956738) filed by Medici Therapeutics on January 13, 2025. The application covers pharmaceutical preparations for the treatment of cancer, immune system disorders, and related conditions under an Intent-to-Use basis.
ZONNIC Nicotine Replacement Therapy Trademark Application
The USPTO received trademark application TM98935361 for ZONNIC covering pharmaceutical preparations for nicotine replacement therapy and smoking cessation products. The application was filed on January 3, 2025, under Intent to Use provisions, covering goods including tablets, lozenges, patches, gums, sprays, and pouches containing nicotine for medical purposes.
KALABMD Trademark - Medical and Non-Medical Skin Care Products and Services
USPTO received trademark application TM99072083 for KALABMD filed March 7, 2025. The application covers International Class 044 (medical skin care treatment services) and International Class 003 (medicated and non-medicated topical skin care products including cleansers, lotions, serums, and moisturizers). This is an Intent-to-Use application indicating the applicant plans to use the mark in commerce.
LONGZENITY Trademark Application - Health and Wellness Services
Longzenity, LLC filed an Intent-to-Use trademark application (TM98893990) with the USPTO on December 10, 2024, covering health and wellness services including education, fitness instruction, nutritional supplements, and holistic health services. The application establishes priority rights pending actual use in commerce.
Beyond Age Trademark Application - Anti-Aging Medical Services
The USPTO received a trademark application (Serial No. TM99071378) for BEYOND AGE covering anti-aging medical services and related research activities. The application includes goods and services in Class 044 (Medical Services) and Class 042 (Scientific Research). The applicant filed under an Intent-to-Use basis with an extension request indicating projected use by March 31, 2026.
LABIQ Trademark Application - Intent to Use
The USPTO received an Intent to Use trademark application for LABIQ (TM99032176) under Class 044 (Medical Services). The application covers software for laboratory information management, telemedicine, healthcare operations, medical testing workflow automation, AI analytics, and related services. No compliance deadlines or regulatory requirements are imposed by this filing.
Cerevance trademark TM98830357, pharmaceutical research, neurological treatments
Cerevance trademark TM98830357, pharmaceutical research, neurological treatments
Extension of OMB Generic Clearance for Reviewer Recruitment Forms
ACF requests public comments on extending OMB clearance 0970-0477 for Reviewer Recruitment Forms. No substantive changes proposed to the generic clearance terms; burden estimates have been updated. The clearance covers forms used to recruit reviewers for grant proposals, research/evaluation plans, and other ACF materials. Comment period closes May 1, 2026.
Exclusive Patent License for PEDF Peptides and Retinal Degeneration Treatment
The National Eye Institute, part of the NIH, has published a notice of its intent to grant an Exclusive Patent License to Perpetual Biosciences, Inc. (New York, NY) covering PEDF (Pigment Epithelium-Derived Factor) peptides for treating retinal degeneration. The license would cover multiple patent applications and issued patents across US, Australia, Canada, European, and Japanese jurisdictions. The public comment period closes on April 16, 2026.
NCI Genomic Data Commons Data Submission Request Form
NCI published a 30-day notice seeking public comments on the NCI Genomic Data Commons (GDC) Data Submission Request Form (OMB Control No. 0925-0752). The form is used by investigators to request submission of cancer genomic data into the GDC for data sharing purposes. Comments are due by May 1, 2026. This extends a prior 60-day notice published February 2, 2026, on which no comments were received.
IMPELLA BTR Heart Pump Trademark Application
USPTO filed trademark application TM98142838 for IMPELLA BTR covering implantable cardiac assist devices, specifically heart pumps. The application is filed under Intent-to-Use provisions with a deadline to use the mark by March 31, 2026.
FDA refuses TRADIPITANT Capsules approval, hearing denied
FDA refuses TRADIPITANT Capsules approval, hearing denied
Center for Tobacco Products Enforcement Complaint
The FDA Center for Tobacco Products filed an enforcement complaint on March 31, 2026, under docket FDA-2026-H-3142. The complaint addresses alleged violations of tobacco product regulations. The respondent must respond to the specific allegations contained in the filed complaint.
Tobacco Product Enforcement Complaint
The FDA Center for Tobacco Products (CTP) filed a complaint on March 31, 2026, docketed as FDA-2026-H-3146. The document initiates an enforcement action against a regulated entity regarding tobacco product compliance. The specific allegations and parties involved are contained in the PDF attachment available through Regulations.gov.
YMACA ROOTS Trademark Application for Medical Devices and Therapy Equipment
The USPTO received an Intent-to-Use trademark application (TM99520608) for YMACA ROOTS covering 82 goods and services categories spanning medical devices, therapy equipment, massage apparatus, diagnostic instruments, and personal care products. The application was filed on November 28, 2025, with a stated intent-to-use date of March 30, 2026. This filing establishes a priority date for the applicant's trademark claims in Class 10 (Medical Devices).
Alphacyte trademark medical imaging, diagnostic instruments
Alphacyte trademark medical imaging, diagnostic instruments
DELRIN 4D trademark for medical syringes
USPTO received trademark application TM99532413 for "DELRIN 4D" filed December 5, 2025, under Intent-to-Use basis. The application covers syringes for injections, syringes for medical purposes, and medical patient training devices (needle-free syringes). This is a routine trademark filing in Class 10 (medical devices) with no final registration yet issued.
ADHD Health Education & Advocacy Trademark Registration
The USPTO received trademark application TM98753172 for 'POWER AHEAD ADHD HEALTH, EDUCATION & ADVOCACY DIALOGUE' filed by POWER AHEAD LLC. The application covers downloadable software, educational media, online healthcare information, seminars, and public advocacy services related to ADHD management. The application was filed September 16, 2024, as an Intent-to-Use filing.
Neuropharmagen trademark for pharmacogenetics SAAS platform
USPTO received trademark application TM98671767 for NEUROPHARMAGEN filed by an unspecified applicant on July 29, 2024. The application covers International Class 044 medical services including pharmacogenetic analysis software (SAAS/PAAS), genetic testing and research services, medical diagnostic services, and clinical trial support. The application is filed on an Intent-to-Use basis with a deadline of March 31, 2026.
Health Elevation 360 Trademark Application - Class 44 Health Services
USPTO received trademark application TM98635213 for 'HEALTH ELEVATION 360' covering health, nutrition, and wellness counseling services (Class 44) along with athletic apparel and hair care products. The application was filed on July 5, 2024, under Intent to Use provisions with an extension deadline of March 31, 2026.
PSYCHIATRY DECONSTRUCTED Trademark Renewal
The USPTO renewed trademark registration TM98471657 for PSYCHIATRY DECONSTRUCTED on March 31, 2026. The mark covers medical services including psychiatric consultation, psychological consultation, and healthcare education information. The original application was filed March 27, 2024.
Playhouse Speech Therapy Trademark Renewal
USPTO renewed trademark TM98428511 for Playhouse Speech Therapy on March 31, 2026, extending trademark protection for speech therapy services. This is a routine administrative renewal with no new obligations or policy changes imposed on trademark holders.
Research Data Center Data Security Forms - Proposed Information Collection
The Centers for Disease Control and Prevention published a notice inviting public comment on a proposed information collection titled 'Research Data Center Data Security Forms for Access to Confidential Data.' The National Center for Health Statistics plans to collect information to fulfill data security requirements when providing access to restricted-use microdata for evidence building purposes. Comments are due by June 1, 2026.
Intent-to-Use Trademark Application for Mental Health Fore All
USPTO received an Intent-to-Use trademark application (TM98612564) for MENTAL HEALTH FORE ALL filed on June 21, 2024. The application covers charitable fundraising services, mental health wellness information, and various merchandise including apparel, golf equipment, and drinkware across multiple trademark classes. This is a routine trademark filing with no compliance deadlines or penalties for third parties.
Rabid Bobcat Confirmed in Colleton County; One Person Exposed
The South Carolina Department of Public Health confirmed a bobcat found near Augusta Hwy and Noble Lane in Smoaks, SC tested positive for rabies. One person was exposed and has been referred to their healthcare provider. This is the first animal to test positive for rabies in Colleton County in 2026, with 21 rabies cases reported statewide this year.
Measles Outbreak Status Update - No New Cases Reported
The South Carolina Department of Public Health reports no new measles cases since March 27, maintaining the Upstate outbreak total at 997 cases. The outbreak will be declared over on April 26, 2026, pending 42 consecutive days without new cases. Age breakdown shows 639 cases in ages 5-17, 264 in children under 5, and 87 in adults 18+.
eCTD Format Acceptance and Quality Defect Declaration Requirements for Therapeutic Products
HSA Singapore announced that electronic Common Technical Document (eCTD) format will be officially accepted for therapeutic product regulatory dossier submissions effective 1 April 2026, using SG-HSA eCTD version 1.1. Additionally, applicants must provide an official declaration confirming no known quality defects in CMC dossiers for submissions from 1 June 2026 onward.
Field Safety Notices List
MHRA published its weekly list of Field Safety Notices (FSNs) covering 23-27 March 2026, listing 14 medical device safety notices from manufacturers. Devices affected include cochlear implant batteries, MRI systems, intraocular lenses, mammography systems, surgical staplers, ventilators, and X-ray imaging systems from manufacturers including Advanced Bionics, Canon Medical Systems, Philips, Hologic, and Intuitive Surgical. MHRA publishes these FSNs for information only—healthcare providers who receive notices directly from manufacturers must act on them.
FDA Protein Bar Labeling Class Action: Calorie Calculation Methodology Dispute
JD Supra published an analysis of a newly filed class action against David Protein alleging protein bars labeled as 150 calories actually contain 263-275 calories. The case centers on methodological dispute over caloric calculation, specifically whether esterified propoxylated glycerol (EPG), a largely undigested fat substitute, should be counted using traditional Atwater factors or ingredient-specific metabolic values under FDA's 21 C.F.R. Section 101.9.
United States ex rel. Shea v. eHealth, Inc. - FCA Medicare Advantage Claims
Chief Judge Denise Casper of the District of Massachusetts denied defendants' motions to dismiss in United States ex rel. Shea v. eHealth, Inc., allowing FCA and Anti-Kickback Statute claims to proceed against Medicare Advantage Organizations and e-brokers. The government alleges defendants paid hundreds of millions in marketing funds to steer enrollments and discriminated against disabled beneficiaries from 2016-2021. The case now enters discovery.
FTC Healthcare Task Force Announcement
The FTC announced creation of a dedicated Healthcare Task Force on March 20, 2026, combining antitrust and consumer protection enforcement under a single coordinated initiative. The task force will focus on healthcare consolidation, anticompetitive conduct, pharmacy benefit managers, medical device manufacturers, and deceptive advertising. Led by representatives from the Bureaus of Competition and Consumer Protection, the initiative expands collaboration with HHS and DOJ.
Trademark Strategy, FDA Approval, Brand Protection for Pharma
Adler Pollock & Sheehan P.C. published an informational article on trademark strategy for life science companies, covering the dual regulatory landscape of USPTO trademark registration and FDA naming requirements for pharmaceutical products. The piece discusses practical steps for brand development including early integration of legal, regulatory, and marketing teams, and international protection strategies.
DOJ Corporate Enforcement Policy for Voluntary Self-Disclosure of Criminal Misconduct
The DOJ released its first-ever Department-wide Corporate Enforcement and Voluntary Self-Disclosure Policy for criminal matters, creating a uniform national framework that supersedes all prior component-specific enforcement policies. The CEP applies to all corporate criminal matters except Sherman Antitrust Act violations and establishes three tiers of incentives for companies that voluntarily self-disclose misconduct, cooperate with investigations, and remediate wrongdoing. Under Part I, qualifying companies that meet all requirements and lack aggravating circumstances receive declination of prosecution.
Louisiana closes UnitedHealthcare contract, reassigns Medicaid members
The Louisiana Department of Health announced closure of its contract with UnitedHealthcare, completing the reassignment of approximately 280,000 Medicaid members to other participating managed care organizations. Over 36,000 members selected new plans during the Special Enrollment Period from January 15 to February 15, with remaining members auto-assigned using an algorithm that prioritized family unity and provider continuity. Receiving MCOs are required to honor all existing care authorizations for 60 days following the transition.
Multi-Planar Fixation System orthopedic surgical device
USPTO granted Patent US12588932B2 to inventors Adam J. Cundiff, Nathan G. Peterson, Scott Maling, Mark William Roberts, Jr., and Eli W. Jacobson for a multi-planar fixation system used in orthopedic surgery. The system comprises a body with curved, dorsal, and medial extensions configured to conform to foot anatomy for osteotomy fixation.
Medical Device Inserters and Processes for Insertion and Use
USPTO granted patent US12588928B2 to Abbott Diabetes Care Inc. covering apparatus and methods for inserting medical devices into a subject's skin. The patent includes 20 claims related to inserter mechanisms with cylindrical caps and sleeves for sensor components. The patent was filed on June 7, 2018.
Devices and Methods for Removal of Material in a Vasculature
The USPTO granted patent US12588926B2 to 2MG, Inc. for devices and methods enabling removal of material from vasculature using a catheter that suctions material while rotating, potentially in combination with an external cuff to create a dam. The patent names inventors Mehrdad Farhangnia, Thomas Davis, Theodore Karmon, Brian Carter Wolfe, and Jonathan James Penrod.
Lumbar spondylolysis fracture fixation system
USPTO granted Patent US12588934B1 to inventors Paul Pagano and Matthew D Kitzmiller for a lumbar spondylolysis fracture fixation system. The patent covers a surgical instrumentation set including an anchor, flexible band, hook, inserter, and tensioner device for spinal fracture repair. The patent contains 10 claims and is classified under multiple A61B surgical device categories.
Surgical bone deformity correction tool patent for osteotomy
The USPTO granted patent US12588931B2 to inventor Mahmoud Hafez on March 31, 2026, covering a method and tool for measuring and correcting bone deformities during osteotomy and fracture treatment. The invention uses preoperative imaging to calculate deformity angles and includes a mechanism to guide bone alignment according to a planned trajectory.
Curvafix intramedullary device patent granted
USPTO granted patent US12588930B2 to Curvafix, Inc. on March 31, 2026, covering implantable intramedullary devices enabling delivery of liquid materials into bone channels. The patent includes 22 claims and names Eric Whittaker, Steven Dimmer, and Blake Matsuzaki as inventors. CPC classifications include A61B 17/72 and related surgical device categories.
Deep vein thrombosis thrombectomy device with embolic protection
USPTO granted patent US12588925B2 to Acotec Technologies Limited for a thrombectomy device designed to treat deep vein thrombosis. The device features a coring member to disintegrate blood clots from the proximal side and a catch member anchored on the distal side to prevent embolization. The patent covers 46 claims and is classified under multiple A61B medical device categories.
Minimally Invasive Surgical Dissector Patent
USPTO granted patent US12588924B2 to Children's Medical Center Corporation for a minimally invasive surgical dissector designed for inter-layer procedures. The device features a wedge structure for advancing between tissue layers and actuated jaws for creating working spaces during surgery. Inventors include Pedro Jose del Nido, Borami Shin Lee, Christopher James Payne, and Mossab Ym Saeed. The patent contains 20 claims.
Thrombectomy Device Having Clot Arrestor
USPTO granted Patent No. US12588919B2 to Nventric Corporation on March 31, 2026, covering a mechanical thrombectomy device with a clot arrestor featuring an expandable frame, interior wall defining a lumen, and support wire. The patent names Don Quy Ngo, Sungwoo Min, and Jiyoung Min as inventors.
Clamping lockout for linear surgical stapler
The USPTO granted Patent US12588920B2 to Cilag GmbH International covering a clamping lockout mechanism for linear surgical staplers. The patent describes a lockout arm that prevents improper assembly and transitions to a bypass position only when the latch projection is properly captured. The patent contains 20 claims and was filed on November 8, 2023.
Treatment tool with detachable movable gripping piece
The USPTO granted Patent US12588921B2 to Olympus Corporation for a treatment tool with a detachable movable gripping piece. The patent covers a mechanism allowing controlled movement within a first range and restricted movement in a second range, with the movable piece attachable and detachable at positions within the restricted range. The grant includes 19 claims.
Sterile barriers and sensor sets for a medical device
The USPTO granted patent US12588922B2 to HumanTouch Surgical Ltd covering sterile barriers and sensor configurations for medical devices. The patent, granted on March 31, 2026, includes 2 claims and protects technology that isolates internal components such as battery packs or sensor packs from the environment and patients. Medical device manufacturers and healthcare providers should be aware of this new intellectual property protection.
Medical Device for Treating Fibrous Adhesions
USPTO granted patent US12588923B2 to Aliform Inc. for a device designed to treat fibrous adhesions such as those implicated in cosmetic conditions including dimpling. The patented device comprises an elongate body with user-controllable breaking means actuatable to move between retracted and operative positions to disrupt fibrous connective tissue. Inventors are Victor Suturin and Mikhail Soutorine.
Pedicle Marker Medical Device Patent Grant
USPTO granted Patent US12588917B2 to NEO MEDICAL S.A. for a pedicle marker medical device featuring an elongated tubular body with a plug and non-threaded external surface. The patent, covering 17 claims and inventor Vincent Lefauconnier, was filed on June 17, 2019.
Wright Medical Ankle Replacement System and Method Patent
The USPTO granted Patent US12588916B2 to Wright Medical Technology, Inc. on March 31, 2026, covering an ankle replacement system and method. The patent (32 claims) describes a position adjustment device and surgical technique for tibia resection during ankle replacement procedures. The filing date was July 15, 2024, with application number 18772514.
Inverting capture apparatus with material depots for body lumen procedures
USPTO granted Stryker Corporation Patent US12588918B2 for inverting capture apparatuses designed to remove material from body lumens using a depot system holding flexible tubes in compressed configuration. The patent, covering 20 claims, names inventors Michael P. Wallace, E. Skott Greenhalgh, and Jayson Delos Santos.
LUXA-D Recall - Foreign Capsule Found in Affected Batch
Jamp Pharma is recalling one batch of LUXA-D 2000 units capsules (Lot S2520177, DIN 02442256) from the Canadian market after a capsule containing a foreign product was found in the affected batch. The recall affects wholesalers at the distribution level. Healthcare providers and patients who have this product should verify their inventory and consult their healthcare provider before discontinuing use.
Auro-Canagliflozin Recall - Incorrect DIN on Blister Cards
Health Canada issued a Type III recall for Auro-Canagliflozin 300mg tablets (DIN 02510375) manufactured by Auro Pharma Inc. due to incorrect Drug Identification Number on blister cards. Affected lots XQ3025001A and XQ3025004A are impacted. The recall applies to wholesalers with a depth limited to wholesale distribution.
Surgical saw for actuating a saw blade with an oscillating head
The USPTO granted Patent US12588912B2 to Stryker European Operations Holdings LLC covering a surgical saw with an oscillating head and navigation system integration. The patent claims a method for navigating a surgical saw by attaching reference points to the blade, tracking pointer position against those points, and determining blade orientation relative to the saw. The patent application was filed June 7, 2024, and contains 18 claims.
Vascular Flow Restriction Device Patent Granted
USPTO granted Patent US12588910B1 to Vahaticor, Inc. for vascular flow restriction devices and related systems and methods. The patent covers technology for deploying a flow restriction device in patient vascular systems with the ability to recapture and reposition the device after partial or full deployment, including confirmation of placement via pressure drop measurements in the coronary sinus.
Bone resection method by plunge milling and rasping during total ankle arthroplasty
The USPTO granted Arthrex, Inc. Patent No. US12588915B2 for a system of tibial bone resection using a rasp with rough and smooth curved surfaces designed for use during total ankle arthroplasty. The patent, filed December 2, 2022, covers 13 claims and names Maris Prieditis, Benjamin Chan, and Adam N. Garlock as inventors.
Bone Graft Harvesting Device Patent Grant
The USPTO granted patent US12588913B2 to Medline Industries, LP for a bone graft harvesting device. The device features a cutter section and housing section secured by a removable fastener, with one section having a shaft for drill connection and the other including a scoop for bone removal. The patent was filed August 24, 2023, and contains 9 claims.
Virtual Control Groups to Reduce Animal Testing in Medicines Development
EMA's CHMP has issued a draft qualification opinion for virtual control groups (VCG) to replace concurrent animal control groups in rat dose-range finding studies. The consultation runs from 31 March to 12 May 2026, inviting comments from the scientific community and stakeholders on this new approach methodology (NAM).